HEA Assay: Red Cell Blood Group Antigen Typing by DNA Microarray

Background Information
Testing of the red cell phenotype is often required for patients referred to the blood bank for pre-transfusion testing. The standard method of performing the red cell phenotype is by serology, using reagent antisera specific for the antigens of interest. However, serological phenotyping is labor-intensive, the antisera are expensive and may be in short supply, and the method is not suitable for all patients (e.g., recently transfused patients). The HEA assay is a DNA-based test that overcomes some of the limitations of serological phenotyping. It predicts the probable red cell phenotype by detecting single nucleotide polymorphisms (SNPs) that define many blood group antigens.

Clinical Indications
The HEA Assay is indicated for patient testing when a red cell phenotype is needed but serological phenotyping cannot be performed.

Appropriate candidates for the HEA assay include:
- Recently transfused patients or patients with a positive direct antiglobulin test.
- Patients at high risk for red cell alloimmunization, including patients with sickle cell anemia, and other frequently transfused patients.
- Patients with auto-antibodies that interfere with phenotyping and antibody identification.
- Selected patients with Fyb-negative serological phenotype, for evidence of the Fyb silencing mutation (patients with this mutation generally do not require Fyb-negative red cell units for transfusion).
- Patients who need to be typed for high-prevalence or low-prevalence antigens for which antisera are not readily available.

Blood centers can use the HEA assay to type blood donors for rare red cell phenotypes.

Methodology and Interpretation
For many red cell antigens (notably excluding the ABO and D antigens), allelic differences generally result from SNPs, and detecting these SNPs provides the basis for determining antigen expression. The HEA assay uses a DNA microarray to detect, in a single test, the polymorphisms associated with red cell antigens C/c, E/e, K/k, Jsa/Jsb, Kpa/Kpb, Fya/Fyb, Jka/Jkb, M/N, S/s, Lua/Lub, Doa/Dob, Hy+/Hy-, Jo(a+)/Jo(a-), LWa/LWb, Dia/Dib, Coa/Cob and Sc1/Sc2. The assay also detects the following mutations that cause weak or silent antigen expression: 265C>T and -67T>C in the FY gene, +5G>T in intron 5 and 230 C>T in exon 5 of the GYPB gene.

The HEA assay is performed on DNA extracted from EDTA whole blood. The DNA region of interest is amplified by multiplex PCR, processed into single-stranded DNA and hybridized with allele-specific oligonucleotide probes to detect the relevant SNPs. The hybridization reaction is performed on a semiconductor chip mounted on a slide. Each chip contains beads expressing a library of allele-specific oligonucleotide probes matching either the wild-type or mutant allele. Hybridization of the test DNA with a matching probe results in probe elongation that is visualized by incorporation of a fluorescent label. An imaging system analyzes the intensities of the fluorescent signals for each SNP. Web-based software interprets the polymorphisms and provides a phenotype report with each antigen listed as ‘+’ (present) or ‘0’ (absent). For selected cases, review of the genotype report provides additional useful information, such as mutations that result in weak or silent expression of Fyb, and RHCE mutations that determine the VVS phenotype.

Limitations of the Assay
- The HEA assay has been validated for patient use by the Cleveland Clinic Section of Transfusion Medicine, but it is not yet licensed by the FDA.
- The assay does not detect all clinically significant antigens.
• Assay results could be misleading, because the genotype may not always reflect the phenotype. Reasons for a genotype-phenotype discrepancy include rare polymorphisms (e.g., those found in ethnic minority populations) that are not represented in the assay, and undetected silent phenotype due to mutation that is not analyzed by the assay. Discrepancies between the molecular type and the expressed phenotype must be investigated.

• Assay results should be interpreted cautiously for patients transfused with non-leukocyte-reduced blood, infants, hematopoietic stem cell transplant recipients, and patients with severe leukopenia or leukocytosis.

References

Test Overview

<table>
<thead>
<tr>
<th>Test Name</th>
<th>HEA Assay</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordering Mnemonic</td>
<td>SQHEA</td>
</tr>
<tr>
<td>Specimen Requirements</td>
<td>EDTA whole blood (pink-top) tube, refrigerated. Blood bank requirements apply for sample collection, labeling and phlebotomist identification.</td>
</tr>
<tr>
<td>Clinical Information</td>
<td>This assay predicts the red cell antigen phenotype based on the patient’s genotype. The test is interpreted by a pathologist in the context of the patient’s clinical and immunohematological findings.</td>
</tr>
<tr>
<td>Disclaimers or Notations</td>
<td>This test uses a reagent or kit labeled by the manufacturer as “research use only” and it is used per manufacturer’s instructions. Its performance characteristics were determined by Cleveland Clinic’s Robert J. Tomsich Pathology and Laboratory Medicine Institute in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration. These results are not intended as the sole means for clinical diagnosis or patient management decisions. There are situations where the genotype of a person may not reflect the red cell phenotype. Mutations that inactivate gene expression or rare new variant alleles may not be identified in this assay.</td>
</tr>
<tr>
<td>Billing Code</td>
<td>87880</td>
</tr>
<tr>
<td>CPT Code</td>
<td>81479(x1)</td>
</tr>
</tbody>
</table>

Technical Information Contact:
Karen McCasson, MT
216.444.4091
mccass@ccf.org

Scientific Information Contacts:
Suneeti Sapatnekar, MD
216.444.3508
sapatns@ccf.org
Priscilla Figueroa, MD
216.444.6543
figuerp@ccf.org